The CAR-T therapy developer has raised more than $178 million since its establishment in 2017.
Chinese biotech companies raised a total of $2.64 billion from 28 disclosed deals in August.
Everest will pay Suzhou Sinovent and SinoMab BioScience up to $561 million to license the global rights to BTK inhibitor XNW1011, four days after the mRNA transaction with Providence that is worth over $500 million.
BeiGene's BTK inhibitor Brukinsa received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory (r/r) marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
Cancer drug developer InnoCare, known for its BTK inhibitor Yinuokai (orelabrutinib), is now seeking to raise RMB4 billion ($621 million) on Shanghai's STAR market.
Alebund Pharmaceuticals, a renal disease specialist based in Shanghai, has secured $54.5 million in a Series B+ round to support its clinical programs and construction of a manufacturing site. The pro
MingMed, which was founded in October 2019, boasts a pipeline that covers ophthalmology, small molecule immuno-oncology, gene editing-based immunotherapy, medical aesthetics, and pet medicine.
Cytovia Therapeutics and its Chinese joint venture CytoLynx Therapeutics have raised $45 million to move their cell therapy candidates to IND stage and support the trials.